Vaccine News and Research

Latest Vaccine News and Research

New vaccine candidate shows great promise at fighting respiratory syncytial virus

Johns Hopkins Bloomberg School of Public Health researchers say a new candidate vaccine against respiratory syncytial virus (RSV) made with a weakened version of the virus shows great promise at fighting the disease, the leading cause of hospitalization for children under the age of one in the U.S.

5 Nov 2015

ESCMID, ESWI call for increased flu vaccination coverage amongst healthcare professionals

The European Society of Clinical Microbiology and Infectious Disease (ESCMID) – an organization that explores risk assessment, knowledge sharing and best practices in the fight against infectious disease – is calling on the healthcare industry to lead by example and implement universal flu vaccination for healthcare workers.

5 Nov 2015

Johnson & Johnson signs definitive agreement to purchase Novira Therapeutics

Johnson & Johnson today announced a definitive agreement to acquire Novira Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus (HBV) infection.

4 Nov 2015

Study provides novel insight into the evolution of hepatitis A virus and how it spreads to humans

Researchers at the University of North Carolina at Chapel Hill are part of an international team led by the University of Bonn, Germany, who have found a link between the origin of hepatitis A virus (HAV) and small mammals.

4 Nov 2015

Pediatricians send away families who refuse to vaccinate their children

One in five pediatricians dismiss families who refuse to vaccinate their children, according to findings published today in the journal Pediatrics and based on research by faculty from the University of Colorado School of Medicine on the Anschutz Medical Campus.

3 Nov 2015

Experts call on U.S. and Mexican governments to reduce risk of Chagas disease

Chagas disease -- the third most common parasitic infection in the world -- affects approximately 7.5 million people, mostly in Latin America. To help reduce outbreaks of this disease in their countries, the United States and Mexican governments should implement a range of programs as well as fund research for the development of Chagas vaccines and treatments, according to a new policy brief by tropical-disease and science policy experts at Rice University's Baker Institute for Public Policy.

3 Nov 2015

FHI 360, Accelovance collaborate to serve international drug development research efforts

Accelovance, Inc. (Accelovance), a global contract research organization (CRO) focusing in Oncology, Vaccines, and General Medicine and FHI 360, a global nonprofit organization with CRO capabilities focusing on clinical research in developing countries, have entered into a strategic alliance to more comprehensively serve the international drug development research efforts of pharmaceutical, governmental, and nonprofit organizations.

3 Nov 2015

CureVac raises €100M to enable rapid expansion of mRNA development platform, clinical-stage pipeline

CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today announces that it has raised about $110 million (€100 million) to enable accelerated expansion of its industry-leading messenger RNA (mRNA) development platform and clinical-stage pipeline.

3 Nov 2015

Salk scientists uncover enzyme responsible for suppressing deadly lung cancer

Scientists at the Salk Institute have uncovered a molecule whose mutation leads to the aggressive growth of a common and deadly type of lung cancer in humans.

3 Nov 2015

Griffith University uncovers first 3-D image of protein linked to cancer spread

Griffith University's Institute for Glycomics has made scientific history by determining the first three-dimensional image of a protein linked to the spread of cancer.

3 Nov 2015

New initiative launched to accelerate search for effective HIV vaccine

A new 23 million euro initiative to accelerate the search for an effective HIV vaccine begins today. Financed by the European Commission, the European AIDS Vaccine Initiative (EAVI2020) brings together leading HIV researchers from public organisations and biotech companies from across Europe, Australia, Canada and the USA in a focused effort to develop protective and therapeutic HIV vaccines.

2 Nov 2015

Self-disseminating vaccines could prevent EID transmission from animals to humans

The 2014/2015 Ebola outbreak in West Africa shone the spotlight not only on the unpreparedness of local health services and science to deal with the pandemic, but also on the phenomenon of emerging infectious diseases (EIDs).

2 Nov 2015

Around 20% of ethnic school girls not vaccinated against HPV

Around 20 per cent of girls from ethnic minority backgrounds are not being vaccinated against the Human Papilloma Virus (HPV) because they feel they don't need to have it, according to a Cancer Research UK survey presented today at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool*.

2 Nov 2015

New research may offer strategies for developing toxoplasma-inactivated vaccine

Toxoplasma gondii is a common parasite which causes the development of fatal encephalosis or pneumonia in immunodeficient patients under treatment of AIDS or cancer.

31 Oct 2015

UofL evaluates safety of new therapeutic vaccine in women with HPV 16, 18 infections

Cervical cancer is the fourth most frequently occurring cancer in women. Human papillomavirus (HPV) is present in 99 percent of cervical cancers and is considered to be their cause. While most HPV infections will clear naturally within a few years, there has been no treatment available to hasten or improve the chance of natural eradication.

31 Oct 2015

First patient of U.S. phase 1 trial treated with Genticel’s GTL001 candidate for HPV 16/18 infections

Genticel, a clinical-stage biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus, today announces that the first patient of the U.S. phase 1 clinical trial has been vaccinated with GTL001, the company’s first-in-class therapeutic vaccine candidate against HPV 16/18 infections.

31 Oct 2015

Johns Hopkins doctors urge people to get vaccinated against influenza virus

Flu season is upon us again — and yes, you should get the flu vaccine. Doctors at the Johns Hopkins University School of Medicine say everyone 6 months of age and older should get vaccinated against the influenza virus this year.

31 Oct 2015

Specialized type of immunotherapy can boost survival from pancreatic cancer

A new study in mice by researchers at Fred Hutchinson Cancer Research Center has found that a specialized type of immunotherapy — even when used without chemotherapy or radiation — can boost survival from pancreatic cancer, a nearly almost-lethal disease, by more than 75 percent. The findings are so promising, human clinical trials are planned within the next year.

30 Oct 2015

Loyola pediatrician reveals signs and symptoms of childhood rashes

Sniffles, stomach bugs, fever and sore throats are often associated with viruses, but rashes are common in children with viral infections as well.

30 Oct 2015

Basic research for developing toxoplasma vaccine underway

Toxoplasma gondii is a common parasite which causes the development of fatal encephalosis or pneumonia in immunodeficient patients under treatment of AIDS or cancer. Pregnant women who are infected may suffer a miscarriage or the newborn child may suffer from a congenital disease. Currently, a toxoplasma vaccine for humans is not available. Using experimental animals such as mice, basic research for developing an inactivated vaccine is underway.

30 Oct 2015